Natural Product (NP) Details

General Information of the NP (ID: NP1734)
Name
Trandolapril
Synonyms
trandolapril; 87679-37-6; Mavik; Gopten; Odrik; Trandolaprilum [Latin]; RU-44570; RU 44570; UNII-1T0N3G9CRC; Indolapril; C24H34N2O5; 1T0N3G9CRC; RU44570; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; NCGC00182079-02; Trandolaprilum; Udrik; DSSTox_CID_3692; DSSTox_RID_77151; DSSTox_GSID_23692; Odric; Preran; CAS-87679-37-6; CCRIS 6594; Mavik (TN); Trandopril; Trandolapril [USP:INN:BAN]; NCGC00095153-01; CHEMBL1519; SCHEMBL16610; (2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; BIDD:GT0804; Trandolapril (JAN/USP/INN); CHEBI:9649; GTPL6453; DTXSID2023692; HSDB 8392; HMS3262J10; HY-B0592; ZINC1853205; Tox21_111453; Tox21_113152; Tox21_500924; BDBM50369775; s6468; AKOS015843316; AKOS015896050; CCG-222228; DB00519; KS-1467; LP00924; NSC 758939; SDCCGSBI-0633768.P001; NCGC00182079-03; NCGC00261609-01; (2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid; 1H-Indole-2-carboxylic acid, 1-((2S)-2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S,3aR,7aS)-; 1H-Indole-2-carboxylic acid, octahydro-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (2S-(1(R*(R*)),2-alpha,3a-alpha,7a-beta))-; Trandolapril, >=98% (HPLC), white powder; D00383; 679T376; A842336; Q929420; SR-02000000917; SR-02000000917-2; BRD-K28550399-001-01-4; Trandolapril, European Pharmacopoeia (EP) Reference Standard; Trandolapril, United States Pharmacopeia (USP) Reference Standard; (2s,3ar,7as)-1-[(2s)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1h-indole-2-carboxylic acid; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxidanylidene-4-phenyl-butan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid; Trandolapril/(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylicacid
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Hypertension [ICD-11: BA00] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C24H34N2O5
PubChem CID
5484727
Canonical SMILES
CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCCC3CC2C(=O)O
InChI
1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
InChIKey
VXFJYXUZANRPDJ-WTNASJBWSA-N
CAS Number
CAS 87679-37-6
ChEBI ID
CHEBI:9649
TTD Drug ID
D0M5OC
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Paricalcitol      Hyper-parathyroidism     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression CCL5  Molecule Info 
Pathway MAP
Down-regulation Expression COL1A1  Molecule Info 
Pathway MAP
Down-regulation Expression COL3A1  Molecule Info 
Pathway MAP
Down-regulation Expression FN1  Molecule Info 
Pathway MAP
Down-regulation Expression REN  Molecule Info 
Pathway MAP
Down-regulation Expression SNAI1  Molecule Info 
Pathway MAP
Down-regulation Expression TNF  Molecule Info 
Pathway MAP
Down-regulation Expression VIM  Molecule Info 
Pathway MAP
                    Experimental
                    Result(s)		 Combination therapy had additive efficacy in retarding renal scar formation during obstructive nephropathy.
          Candesartan cilexetil      Hypertension     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical trial
                    Experimental
                    Result(s)		 Combination therapy with trandolapril and candesartan cilexetil has an additive effect on the reduction of microalbuminuria in microalbuminuric normotensive type 2 diabetes patients.
          Verapamil      Hypertension     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [4]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical trial
                    Experimental
                    Result(s)		 A fixed-dose combination of trandolapril-verapamil seems to be an effective and safe option for the management of stage 2 hypertension in Mexican patients uncontrolled by monotherapy.
Target and Pathway
Target(s) Angiotensin-converting enzyme 1 (ACE1)  Molecule Info  [5]
KEGG Pathway Renin-angiotensin system Click to Show/Hide
2 Chagas disease (American trypanosomiasis)
3 Hypertrophic cardiomyopathy (HCM)
Pathwhiz Pathway Angiotensin Metabolism Click to Show/Hide
Reactome Metabolism of Angiotensinogen to Angiotensins Click to Show/Hide
WikiPathways ACE Inhibitor Pathway Click to Show/Hide
2 Metabolism of Angiotensinogen to Angiotensins
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6453).
Reference 2 Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009 Dec;76(12):1248-57.
Reference 3 Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes. Clin Exp Nephrol. 2002 Sep;6(3):135-9.
Reference 4 Efficacy of a fixed-dose combination of trandolapril-verapamil in patients with stage 2 hypertension inadequately controlled by monotherapy. Clin Drug Investig. 2005;25(7):445-51.
Reference 5 Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link